Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Corporate Communications
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
Our Science
>
Our Science
>
Poster and Presentation
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Poster and Presentation
2022 ADA Poster
Dorzagliatin, a dual-acting glucokinase activator, improves insulin secretion and glucose sensitivity in glucokinase-maturity-onset diabetes of the young (GK-MODY) and recent-onset type 2 diabetes.
Read More
2022 ADA Poster
Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin.
Read More
2022 ADA Poster
Dorzagliatin Effect in Diabetes Remission (DREAM Study)
Read More
2021 ADA Poster
Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.
Read More
2021 ADA Poster
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)
Read More
2020 ADA Poster
Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)
Read More
<<
<
1
2
3
4
5
>
>>
上一页
下一页
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Subscribe Email
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号
Privacy Statement
Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our
privacy statement
.
Accept
x
MGM-Mirage-media@52ca.net
澳门太阳城
Gaming-platform-service@cswkyt.com
Electronic-demo-hr@optommir.com
书香云集
Wynn-Sports-app-media@76999.net
皇冠博彩
皇冠体育
Betting-on-European-Cup-matches-feedback@puertolindohotel.com
Crown-camp-contactus@shandongshunji.com
易贷网
威尼斯人官网
太阳城
生死书
24K中文网
太阳城平台
欧洲杯比赛投注
Wade-help@miaozhao86.com
沙巴体育
阜阳中公教育
上海老百姓网
迅雷看看
身份证号码查询验证
金鹰国际集团
汉王书城
狩龍戰紀-官方網站
《新水浒Q传》官方网站
哈尔滨银行
返利网
四川职业技术学院
海客乐
MISSHA谜尚官方网站
庄河便民网
站点地图
约瑟传说(赛尔号2)官网